- NewsCategory：
- All Company news Industry news
common83One result
-
0827
Gilead and Galapagos Complete σπ∏¥Closing of Their Tran≈∏sformative Research aεδnd Development Colla✘★₩boration
Gilead Sciences, Inc. and Galapagos NV aγ₽₽nnounced the closing of the gl₽δ™obal research and development collaboration agree∏∞ment signed on July 14, 2019.This agreement has →γreceived clearance fro®¥αγm the U.S. Federal Trade ↓★✔ Commission under the Hart-Scoββ<₩tt-Rodino Antitrust ImprovementΩ↑s Act of 1976 and merger con←π↔trol approval from the Aus '↑trian Federal Competition Authority.Unde&≥r the terms of the agreement, th↔ ε e closing of this trans®★action triggers an upfront license fee payment ε★Ω of $3.95 billion by Gilead to ×₩γδGalapagos. In addition, Gilead has made an equ☆☆ity investment in Galapagos of approximately $1.1∏↔ billion (or approximately €960 mi•→↕βllion) by subscribing₽• for new shares at a pri✘ε₩ce of €140.59 per share, including i•λ★ssuance premium. As a result, Gilead now ow→λ↓σns 13,589,686 ordinary shares of Galaφ pagos, representing approximately 2≤ ₽®2 percent of the curr ™ently outstanding share capit< ←al of Galapagos.“We ≥£are excited to close this unique agr≠↕✘eement, which will generate both long-ter₩♣m strategic value and mutual, immediate benefλ its,” said Daniel O'Day, ♥↔Chairman and Chief Executive O≤fficer of Gilead. “The collaboration reflects Gi∏♦γlead's intent to grow our innova₩σtion network through diverse≠↕™÷ and creative partnerships.”“This agreement iα&↓s about maximizing innova♦≥∞tion based on developing new mode of action m₩€edicines. With the capital provided by Gilead, wΩe aim to progress innovation to p©✘♥↕atients,” said Onno van de>φ> Stolpe, Chief Executive Officer of Galapa≤β™gos.In accordance with BelgiaΩ©←n transparency legislation1, Galapagos n±✘otes that its total share capital currently a®≠£≈mounts to €333,479,569.76; the total n↕↓γumber of securities conferring vo€×↑$ting rights is 61,652,08λ¥>6, which is also the total number of vot♦ing rights (the “denominator”), and all securitie•σs conferring voting righשts and all voting rights are of the same cate×∞÷gory. The total number of rights (wa©φrrants) to subscribe ✘♣♠to not yet issued securities co≤∏nferring voting rights is 5,958,292, whλ©♣ich equals the total number of vot≥↑ing rights that may result≤β♦→ from the exercise of these warra•εnts. Galapagos does not have any convert↔ →ible bonds or shares without voting rights $<outstanding.About Gilead SciencesGilea≥↑×πd Sciences, Inc. is a research-based$≈ biopharmaceutical co&≈Ωmpany that discovers, develops and commercializes↔✘€ innovative medicines in areas of ≥σunmet medical need. The company strives∏≠• to transform and simplify care≤<≈€ for people with life-threatening illnesses ar "ound the world. Gilead has opera↕α$★tions in more than 35 co "©untries worldwide, with he≥ ÷&adquarters in Foster City, California. For mσ≠φore information on Gilead Sci∏≈≠£ences, please visit the company’s websi₩↕'te at www.gilead.com.About GalapagosGalσ≤γapagos (Euronext & NASDAQ: GLPG) discove¥₽©§rs and develops small molecule medicines wiλ<$'th novel modes of action, three ofε☆✔ which show promising patient rβ₽esults and are currently in late-stage d←₹evelopment in multiple diseases. The comα×∏pany’s pipeline comprises Phase 3 through to d>iscovery programs in§₽ inflammation, fibrosis, osteoarthri≤↕€$tis and other indications. Galapagos’ €≈¶εambition is to become a leλ€™σading global biopharmaceutical company foc₩←used on the discovery, ¶™ development and commercialization of innov¥¥λative medicines. More information≠☆ at www.glpg.com.Gilead Forward-Looking StatemβλεentsThis press release incπludes forward-looking statements within≈β✘ the meaning of the Private Securitie₹σ♠s Litigation Reform Act of 1995, related ≈• σto Gilead, Galapagos and the globa§₹$'l research and development co±§©×llaboration agreement that ₩✔ are subject to risks, uncertainγβties and other factors. All state₹'$∞ments other than statement≈∞©♣s of historical fact are sta"☆tements that could be deemed forwa'↑rd-looking statements, including all state♠™ ments regarding the intent, belief ε®↕×or current expectfrom pharma focus a≥₩♦ isathe 2019 Asia-pacific Pharmaceutical IP↑≥↑≥ Leader Summit will be held in¥ Beijing on November 14-15, and will attract✘★ more than 500 industry experts from do±αmestic and foreign pharmaceutical™&₩™ companies, biotechnology compa↑₽≤↕nies, governments, associations, law fiσ$&rms, intellectual property agents and othe♣∏r companies to attend.Official registration ¥&÷ and consultation channels:Contact：AnnPhone:★€σ§ 021-65650305Email：Marketing@zenseeg↑δroup.comhttp://en.zenseegro↔γup.com/p/510934/ -
1230
Bid for $40 million disa↑'¥ster insurance program fails
Rosalia de Leon, treasurer of the PhilipΩ§pines, said that the govern₹↔§©ment is unable to find reinsurers for a 2 bil Ω≤lion Philippine pesos ($40 mill ∞δ¥ion) national disaster indemnity insurance prΩ♠ogram after a failed φ'∏αbid this month, Business Inquirer↓ reports. The government was looking to insur™₹'Ωe the bridges, roads and highways in 25 p∑✘rovinces as well as schools in↑↑< 32 provinces and the national capital π✘€δregion against fire, lightning and natural catastrophes.Organizer←∞₩：China Insurance Digital & A≥↑I Development 2020Web:http://en.zenseegrφσ÷✘oup.com/p/560573/Contact:Ann 021-65650β♣∏₽305 -
0826
Enable Injections Enters into Strategic Partners↑₹€÷hip with Genentech, a Member of the Roche Gro♠¶ $up
Enable Injections, Inc. (Enable), a ≠©company developing and ♣¥manufacturing investigational wearable infus€♦ion devices for combination products, tod>ay announced it has entered into a dev↑€∞→elopment agreement with Genentech, a ✔ •φmember of the Roche Group. The enFuse™, under dev↔ ∏≠elopment by Enable, will÷≈$ enable patient-administeα™red subcutaneous delivery of high-volume t₩↑herapeutics.This Enable and Genen↑€¥tech partnership includes the potentia∏♠←βl for multiple molecule deσ®£★velopment programs incorporatin₩ g long-term manufacturing and supply arrangeme∑®≈±nts.The Enable enFuse ≈π÷≠is an on-body drug delivery platform¥∑€ with a drug transfer system compatibl★ ♣e with standard syringes or vial container₩£ formats. The wearable e ₹ nFuse platform is being developed for subcutaneou∑Ω"s administration of large-¶★γ×volumes potentially ranging up to 50 mL. Deγ£signed for ease of use<€"÷, the enFuse has the potential to provide pa↓δtients and their caregivers an alternative d®"☆≈elivery method for subcutane ≈§ous administration of pa£≠renteral therapies outside of a c•ε¶≠linical setting."Enable Injections is pleased to partner with Gen$γ ®entech in its focus on delivering patient-focus £ed solutions," said Michael D. Hooven, Ena♥ ble Injections Founder, < President and CEO. "With the enFuse paired to dγ♥∏eliver selected subc§✔utaneous therapeutics, it can potenti"λally benefit patients worldwide."the 20₩®19 Asia-pacific Pharmaceutical IP L> eader Summit will be held in ♦γBeijing on November 14-15, and♠→π÷ will attract more than 500 ¥✔∏★industry experts from domestic and foreig'♣>≈n pharmaceutical companies, biotechnology comp↕$anies, governments, associatioε ns, law firms, intellectual propert•↕©↕y agents and other companies to attend.Official r↓₩ egistration and consultation channels:Conta& ×εct：AnnPhone: 021-65650305Email：Market₩λ ing@zenseegroup.comhttσ¶p://en.zenseegroup.com/p/510934/ -
1227
Health Provider in Arizona to Pφ∞♣£ay $6M Settlement in Breach
A Phoenix, Ariz.-based health provider ✘☆✔'has agreed to settle a lawsuit over a coλβ&'mputer data breach that may have ∑÷Ωcompromised health and personal data of a©≠≥bout 3 million patient←>$₽s, employees, health insur↑∏λ&ance customers and others.The class acti≤α∑on lawsuit against Banner Hea®¶Ωlth stemmed from a 2016 cyberattack thλ±at exposed the information, The Arizo ↓∞¶na Republic reports.The settlementΩ'÷, up to $6 million, includes free insu₹≈'rance coverage for claims of up "∑εαto $1 million to cover financi§εal losses and two year₹ s of free credit monitori ✘φng through Identity Guard Total, of♦>↑≤ficials said.When the breach o× ☆✔ccurred, Banner Heal©₽δth initially gave those ↓✔affected a year of free credit≈ε monitoring, officials♥→ said.Those affected would be able to file cla₹∞ims for up to $500 for ordinary expe£±π±nses or up to $10,000♦✘λ for extraordinary expense"∑π reimbursement such as lost time< at work or professional help with identity theft≈≠ issues under the settlement ¥© agreement, company officials said.“∞€All things considered, this settleβ♥♠ment compares very favorably with those t ✘hat have been approved in other da✔<ta breach cases,” said Andrew Friedman, onσ×λ£e of the lawyers representingπ✔♣ the plaintiffs.The settlement was gΩ'✘€ranted preliminary approval and is sub∑∑☆∑ject to final court approval April 21, offic∑Ω&ials said.“This is sti' ₩≥ll a pending legal matter, so we ®£are unable to discuss det♠σails. However, we are hopeful that it will be₽σ resolved soon, at which time♦§ those who were impacted can learn addition×σal information,” provid♣ er spokeswoman Becky Armendariz sai×™d.Banner Health has also agreed to improve §¥₽₽its information security systems, offi≈cials said.“In the meantime, data se©αλcurity is one of our h∞Ω®∞ighest priorities and we con©'→tinue to work diligently to protect §§the sensitive information of our patien≠α'ts and employees,” officials✘γ₹ said.Organizer：China Insurance Digital & A®δσI Development 2020Web:http://en.zenseegro ✘÷up.com/p/560573/Contact:Ann 021-65650305 -
0823
Innovent Enters a Licensing Agreement•> with Lilly to Develop & Commercialize a¥'®Ω Novel Diabetes Medicine in China
Innovent Biologics, Inc.↑≤π, a world-class biopharmaceu™β→tical company that develops and commercial¥✘izes high quality medic↔ines, today announced that it has entere™™d into a licensing agreement with Eli Lilly and Company (Li>Ω₽lly) for the development and potential commerci€λ↕'alization of oxyntomoduli$↑n analog, OXM3, in China. OXM3 is a dual GLP-1 a↕↕&★nd glucagon receptor agonist that will entπ±er China as a potential <<best-in-class, mid-stage clinica'∏l development diabetes compound. Financi¥ ×∏al terms of the agreement were not d£•≠isclosed."Innovent is committed≈¶✔₽ to develop and commercialize high q¶®uality biopharmaceuticals that are afforda♦©ble to ordinary people. This "δlicense agreement marks an importanβ"t step for Innovent as it strengthens our portfo₹≠lio by adding a potential £₽★best-in-class clinical stage metabolic λ↑≥™disease asset, and it br<✘oadens the therapeutic areas we ☆αcover to include diabetes," sa™♠id Michael Yu, Founder, Chief Execu©↔£tive Officer and Chairman of Innovent. ∞♠≈☆"Diabetes is recognized as thπαΩ₽e world's fastest gro↕®wing chronic condition. China has a greater num≈ ber of diabetic patients than<≈<£ any other country in tΩφπhe world with around 114 million people suffering™δ♦ from the disease. We are'α® excited to license this molecule from"$ Lilly, and we look forward to developing OXφ∑♥M3 as a potential innovative treatment that ®£could address a significant unmet medical need in×÷∑ China."the 2019 Asia-paci♣✔fic Pharmaceutical IP× ♠ Leader Summit will be ♠ λ™held in Beijing on November 14-15, and w♣ βill attract more than 500 industry e↓Ω♦xperts from domestic and foreign pharmaceutiδλ÷cal companies, biotechnology companies, g≈≠overnments, associations, law firms, intelle∏&Ωctual property agents and other companies to ≈ασattend.Official regis₹♦↔tration and consultation channels:C δ&ontact：AnnPhone: 021-65650305Email：M↔<>arketing@zenseegroup.comhttp://www.zens±¶↔<eegroup.com/forms/view/22113/
Contact Us
Zensee_Daystar online
© 2011-2016